Clinical pharmacology of n-3 polyunsaturated fatty acids: Non-lipidic metabolic and hemodynamic effects in human patients

Atherosclerosis Supplements

Volumn 14, Issue 2, 2013, Pages 230-236

  Marangoni, Franca ^a   Poli, Andrea ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Endothelial function; Inflammation; N 3 polyunsaturated fatty acids; Plaque stability

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DOCOSAHEXAENOIC ACID; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ICOSAPENTAENOIC ACID; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MACROPHAGE ELASTASE; MATRILYSIN; OMEGA 3 FATTY ACID; PADGEM PROTEIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOXANE B2; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR; AUTACOID; BIOLOGICAL MARKER; CELL ADHESION MOLECULE;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DRUG EFFICACY; GENE EXPRESSION; HEART FAILURE; HEART RATE; HEMODYNAMICS; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PLEIOTROPY; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; VASODILATATION; BLOOD; CARDIOVASCULAR DISEASES; DRUG EFFECTS; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CELL ADHESION MOLECULES; ENDOTHELIUM, VASCULAR; FATTY ACIDS, OMEGA-3; HEMODYNAMICS; HUMANS; INFLAMMATION MEDIATORS; PLATELET AGGREGATION; TREATMENT OUTCOME;

EID: 84881638673     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/S1567-5688(13)70003-5     Document Type: Article

References (53)

1. Duda MK, O'Shea KM, Stanley WC Omega-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential. Cardiovasc Res 2009, 84:33-41.
2. Calder PC The role of marine omega-3 (n-3) fatty acids in inflammatory processes, atherosclerosis and plaque stability. Mol Nutr Food Res 2012 Jul, 56(7):1073-1080. 10.1002/mnfr.201100710.
3. Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J 2011 Jul, 162(1):115. 24.e2. 10.1016/j.ahj.2011.04.006.
4. Gao LG, Cao J, Mao QX, Lu XC, Zhou XL, Fan L Influence of omega-3 polyunsaturated fatty acid-supplementation on platelet aggregation in humans: a meta-analysis of randomized controlled trials. Atherosclerosis 2013 Feb, 226(2):328-334. 10.1016/j.atherosclerosis.2012.10.056.
5. Serebruany VL, Miller M, Pokov AN, Lynch D, Jensen JK, Hallén J, Atar D Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia. Cardiology 2011, 118(3):187-194. Epub 2011 Jun 22. 10.1159/000329300.
6. Lev EI, Solodky A, Harel N, Mager A, Brosh D, Assali A, Roller M, Battler A, Kleiman NS, Kornowski R Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation. J Am Coll Cardiol 2010 Jan 12, 55(2):114-121. 10.1016/j.jacc.2009.08.039.
7. Phang M, Lincz LF, Garg ML Eicosapentaenoic and docosahexaenoic acid supplementations reduce platelet aggregation and hemostatic markers differentially in men and women. J Nutr 2013 Apr, 143(4):457-463. Epub 2013 Feb 6. 10.3945/jn.112.171249.
8. Dyerberg J, Bang HO, Hjorne N Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr 1975, 28:958-966.
9. Mori TA, Woodman RJ The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr Metab Care 2006, 9:95-104.
10. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens 2002 Aug, 20(8):1493-1499.
11. Cicero AF, Derosa G, Di Gregori V, Bove M, Gaddi AV, Borghi C Omega 3 polyunsaturated fatty acids supplementation and blood pressure levels in hypertriglyceridemic patients with untreated normal-high blood pressure and with or without metabolic syndrome: a retrospective study. Clin Exp Hypertens 2010 Jan, 32(2):137-144. 10.3109/10641960903254448.
12. Mori TA, Bao DQ, Burke V, Puddey IB, Beilin LJ Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension 1999 Aug, 34(2):253-260.
13. Nestel P, Shige H, Pomeroy S, Cehun M, Abbey M, Raederstorff D The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am J Clin Nutr 2002, 76:326-330.
14. Hartweg J, Farmer AJ, Holman RR, Neil HA Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes. Diabetologia 2007 Feb, 50(2):250-258. Epub 2006 Nov 21.
15. Stark KD, Holub BJ Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. Am J Clin Nutr 2004, 79:765-773.
16. Grimsgaard S, Bonaa KH, Hansen JB, et al. Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans. Am J Clin Nutr 1998, 68:52-59.
17. Mozaffarian D, Geelen A, Brouwer IA, Geleijnse JM, Zock PL, Katan MB Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. Circulation 2005 Sep 27, 112(13):1945-1952. Epub 2005 Sep 19.
18. Kelley DS, Adkins Y Similarities and differences between the effects of EPA and DHA on markers of atherosclerosis in human subjects. Proc Nutr Soc 2012 May, 71(2):322-331. Epub 2012 Feb 28. 10.1017/S0029665112000080.
19. Goodfellow J, Bellamy MF, Ramsey MW, Jones CJ, Lewis MJ Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. J Am Coll Cardiol 2000 Feb, 35(2):265-270.
20. Schiano V, Laurenzano E, Brevetti G, De Maio JI, Lanero S, Scopacasa F, Chiariello M Omega-3 polyunsaturated fatty acid in peripheral arterial disease: effect on lipid pattern, disease severity, inflammation profile, and endothelial function. Clin Nutr 2008 Apr, 27(2):241-247. Epub 2008 Jan 31. 10.1016/j.clnu.2007.11.007.
21. Egert S, Stehle P Impact of n-3 fatty acids on endothelial function: results from human interventions studies. Curr Opin Clin Nutr Metab Care 2011 Mar, 14(2):121-131. 10.1097/MCO.0b013e3283439622.
22. Wang Q, Liang X, Wang L, Lu X, Huang J, Cao J, Li H, Gu D Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. Atherosclerosis 2012 Apr, 221(2):536-543. 10.1016/j.atherosclerosis.2012.01.006.
23. Xin W, Wei W, Li X Effect of fish oil supplementation on fasting vascular endothelial function in humans: a meta-analysis of randomized controlled trials. PLoS One 2012, 7(9):e46028. 10.1371/journal.pone.0046028.
24. Din JN, Archer RM, Harding SA, Sarma J, Lyall K, Flapan AD, Newby DE Effect of ω-3 fatty acid supplementation on endothelial function, endogenous fibrinolysis and platelet activation in male cigarette smokers. Heart 2013 Feb, 99(3):168-174. 10.1136/heartjnl-2012-302924.
25. Wong AT, Chan DC, Barrett PH, Adams LA, Watts GF Supplementation with n3 fatty acid ethyl esters increases large and small artery elasticity in obese adults on a weight loss diet. J Nutr 2013 Apr, 143(4):437-441. 10.3945/jn.112.169359.
26. Dangardt F, Osika W, Chen Y, Nilsson U, Gan LM, Gronowitz E, Strandvik B, Friberg P Omega-3 fatty acid supplementation improves vascular function and reduces inflammation in obese adolescents. Atherosclerosis 2010 Oct, 212(2):580-585. 10.1016/j.atherosclerosis.2010.06.046.
27. Okumura T, Fujioka Y, Morimoto S, et al. Eicosapentaenoic acid improves endothelial function in hypertriglyceridemic subjects despite increased lipid oxidizability. Am J Med Sci 2002, 324:247-253.
28. Engler MM, Engler MB, Malloy M, et al. Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: Results from the EARLY study. Int J Clin Pharmacol Ther 2004, 42:672-679.
29. Mori TA, Watts GF, Burke V, et al. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation 2000, 102:1264-1269.
30. Cottin SC, Sanders TA, Hall WL The differential effects of EPA and DHA on cardiovascular risk factors. Proc Nutr Soc 2011 May, 70(2):215-231. Epub 2011 Feb 24. 10.1017/S0029665111000061.
31. Ridker PM Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107:363-369.
32. Calder PC N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids 2003 Apr, 38(4):343-352.
33. Bannenberg G, Serhan CN Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochim Biophys Acta 2010, 1801(12):1260-1273.
34. Farzaneh-Far R, Harris WS, Garg S, Na B, Whooley MA Inverse association of erythrocyte n-3 fatty acid levels with inflammatory biomarkers in patients with stable coronary artery disease: The Heart and Soul Study. Atherosclerosis 2009 Aug, 205(2):538-543. 10.1016/j.atherosclerosis.2008.12.013.
35. Kiecolt-Glaser JK, Belury MA, Andridge R, Malarkey WB, Hwang BS, Glaser R Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: a randomized controlled trial. Brain Behav Immun 2012 Aug, 26(6):988-995. 10.1016/j.bbi.2012.05.011.
36. Sijben JW, Calder PC Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease. Proc Nutr Soc 2007 May, 66(2):237-259.
37. Itariu BK, Zeyda M, Hochbrugger EE, Neuhofer A, Prager G, Schindler K, Bohdjalian A, Mascher D, Vangala S, Schranz M, Krebs M, Bischof MG, Stulnig TM Long-chain n-3 PUFAs reduce adipose tissue and systemic inflammation in severely obese nondiabetic patients: a randomized controlled trial. Am J Clin Nutr 2012 Nov, 96(5):1137-1149. 10.3945/ajcn.112.037432.
38. Doenyas-Barak K, Berman S, Abu-Hamad R, Golik A, Rahimi-Levene N, Efrati S N-3 fatty acid supplementation to routine statin treatment inhibits platelet function, decreases patients' daytime blood pressure, and improves inflammatory status. Eur J Clin Pharmacol 2012 Aug, 68(8):1139-1146. Epub 2012 Feb 25. 10.1007/s00228-012-1235-4.
39. Kelley DS, Siegel D, Fedor DM, Adkins Y, Mackey BE DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men. J Nutr 2009 Mar, 139(3):495-501. 10.3945/jn.108.100354.
40. Moertl D, Berger R, Hammer A, Hutuleac R, Koppensteiner R, Kopp CW, Steiner S Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure. Thromb Haemost 2011 Sep, 106(3):457-465. 10.1160/TH-11-03-0169.
41. Abe Y, El-Masri B, Kimball KT, et al. Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol 1998, 18:723-731.
42. Eschen O, Christensen JH, De Caterina R, et al. Soluble adhesion molecules in healthy subjects: a doseresponse study using n-3 fatty acids. Nutr Metab Cardiovasc Dis 2004, 14:180-185.
43. Thies F, Garry JMC, Yaqoob P, Rerkasem K, Williams J, Shearman CP, Gallagher PJ, Calder PC, Grimble RF Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003, 361:477-485.
44. De Caterina R, Madonna R, Bertolotto A, Schmidt EB n-3 fatty acids in the treatment of diabetic patients: biological rationale and clinical data. Diabetes Care 2007 Apr, 30(4):1012-1026. Epub 2007 Jan 24.
45. Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJ, Gudmundsen O, Vige R, Payne SP, Ye S, Shearman CP, Gallagher PJ, Grimble RF, Calder PC Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis 2010 Sep, 212(1):252-259. 10.1016/j.atherosclerosis.2010.05.022.
46. Amano T, Matsubara T, Uetani T, Kato M, Kato B, Yoshida T, Harada K, Kumagai S, Kunimura A, Shinbo Y, Kitagawa K, Ishii H, Murohara T Impact of omega-3 polyunsaturated fatty acids on coronary plaque instability: an integrated backscatter intravascular ultrasound study. Atherosclerosis 2011 Sep, 218(1):110-116. 10.1016/j.atherosclerosis.2011.05.030.
47. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986 Dec, 74(6):1399-1406.
48. Robinson JG, Stone NJ Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am J Cardiol 2006 Aug 21, 98(4A):39i-49i. Epub 2006 May 30.
49. Sacks F, Stone P, Gibson C, Silverman D, Rosner B, Pasternak R, for the HARP Research Group Controlled trial of fish oil for regression of human coronary atherosclerosis. J Am Coll Cardiol 1995, 25:1492-1498.
50. von Schacky C, Angerer P, Kothny W, Thiesen K, Mudra H The effect of dietary omega-3 fatty acids on coronary atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999, 130:554-562.
51. Anderson JS, Nettleton JA, Herrington DM, et al. Relation of omega-3 fatty acid and dietary fish intake with brachial artery flow-mediated vasodilation in the Multi-Ethnic Study of Atherosclerosis. Am J Clin Nutr 2010, 92:1204-1213.
52. Mita T, Watada H, Ogihara T, Nomiyama T, Ogawa O, Kinoshita J, Shimizu T, Hirose T, Tanaka Y, Kawamori R Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. Atherosclerosis 2007 Mar, 191(1):162-167. Epub 2006 Apr 17.
53. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J Effects of omega-3 fatty acids on coronary restenosis, intima-media thickness, and exercise tolerance: a systematic review. Atherosclerosis 2006 Feb, 184(2):237-246.